In summary, results of our in vitro and mouse xenograft in vivo studies indicated that Fdcyd treatment was synthetic lethal with PBRM1 loss in ccRCC and Fdcyd could serve as a novel therapeutic agent for renal cancer with PBRM1 deficiency. Here, PBRM1 is linked to nonpapillary renal cell carcinoma.